Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Sunshine Biopharma (SBFM) over the last 14 years, with Q3 2025 value amounting to $5.0 million.

  • Sunshine Biopharma's Operating Expenses rose 630.84% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 1652.25%. This contributed to the annual value of $20.7 million for FY2024, which is 1995.55% up from last year.
  • Per Sunshine Biopharma's latest filing, its Operating Expenses stood at $5.0 million for Q3 2025, which was up 630.84% from $6.6 million recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Operating Expenses registered a high of $24.9 million during Q4 2022, and its lowest value of $397842.0 during Q4 2021.
  • Its 5-year average for Operating Expenses is $4.6 million, with a median of $4.1 million in 2023.
  • As far as peak fluctuations go, Sunshine Biopharma's Operating Expenses surged by 616151.94% in 2022, and later plummeted by 7874.11% in 2023.
  • Over the past 5 years, Sunshine Biopharma's Operating Expenses (Quarter) stood at $397842.0 in 2021, then soared by 6161.52% to $24.9 million in 2022, then plummeted by 78.74% to $5.3 million in 2023, then grew by 16.59% to $6.2 million in 2024, then dropped by 19.18% to $5.0 million in 2025.
  • Its Operating Expenses was $5.0 million in Q3 2025, compared to $6.6 million in Q2 2025 and $5.2 million in Q1 2025.